Advice
Following a full submission
capecitabine (Xeloda®) is accepted for use within NHS Scotland for the treatment of metastatic colorectal cancer.
The convenience of oral administration may allow changes to service delivery that have individual patient or organisational benefits, though these may be lessened when it is used in regimens whose other components require intravenous administration.
Download detailed advice102KB (PDF)
Medicine details
- Medicine name:
- capecitabine (Xeloda)
- SMC ID:
- 507/08
- Indication:
- Metastatic colorectal cancer
- Pharmaceutical company
- Roche
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Full
- Status
- Accepted
- Date advice published
- 13 October 2008